BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

614 related articles for article (PubMed ID: 16324835)

  • 1. In transit/local recurrences in melanoma patients after sentinel node biopsy and therapeutic lymph node dissection.
    Rutkowski P; Nowecki ZI; Zurawski Z; Dziewirski W; Nasierowska-Guttmejer A; Switaj T; Ruka W
    Eur J Cancer; 2006 Jan; 42(2):159-64. PubMed ID: 16324835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The survival benefit to patients with positive sentinel node melanoma after completion lymph node dissection may be limited to the subgroup with a primary lesion Breslow thickness greater than 1.0 and less than or equal to 4 mm (pT2-pT3).
    Nowecki ZI; Rutkowski P; Michej W
    Ann Surg Oncol; 2008 Aug; 15(8):2223-34. PubMed ID: 18506535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival analysis and clinicopathological factors associated with false-negative sentinel lymph node biopsy findings in patients with cutaneous melanoma.
    Nowecki ZI; Rutkowski P; Nasierowska-Guttmejer A; Ruka W
    Ann Surg Oncol; 2006 Dec; 13(12):1655-63. PubMed ID: 17016755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multivariable analysis comparing outcome after sentinel node biopsy or therapeutic lymph node dissection in patients with melanoma.
    van Akkooi AC; Bouwhuis MG; de Wilt JH; Kliffen M; Schmitz PI; Eggermont AM
    Br J Surg; 2007 Oct; 94(10):1293-9. PubMed ID: 17702089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sentinel lymph node biopsy in melanoma: a micromorphometric study relating to prognosis and completion lymph node dissection.
    Debarbieux S; Duru G; Dalle S; Béatrix O; Balme B; Thomas L
    Br J Dermatol; 2007 Jul; 157(1):58-67. PubMed ID: 17501957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of non-sentinel node status and outcome in sentinel node-positive melanoma patients.
    Roka F; Mastan P; Binder M; Okamoto I; Mittlboeck M; Horvat R; Pehamberger H; Diem E
    Eur J Surg Oncol; 2008 Jan; 34(1):82-8. PubMed ID: 17360144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Melanoma patients with positive sentinel nodes who did not undergo completion lymphadenectomy: a multi-institutional study.
    Wong SL; Morton DL; Thompson JF; Gershenwald JE; Leong SP; Reintgen DS; Gutman H; Sabel MS; Carlson GW; McMasters KM; Tyler DS; Goydos JS; Eggermont AM; Nieweg OE; Cosimi AB; Riker AI; G Coit D
    Ann Surg Oncol; 2006 Jun; 13(6):809-16. PubMed ID: 16604476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular and biochemical testing in stage III melanoma: multimarker reverse transcriptase-polymerase chain reaction assay of lymph fluid after lymph node dissection and preoperative serum lactate dehydrogenase level.
    Nowecki ZI; Rutkowski P; Kulik J; Siedlecki JA; Ruka W
    Br J Dermatol; 2008 Sep; 159(3):597-605. PubMed ID: 18616789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early (sentinel lymph node biopsy-guided) versus delayed lymphadenectomy in melanoma patients with lymph node metastases : personal experience and literature meta-analysis.
    Pasquali S; Mocellin S; Campana LG; Bonandini E; Montesco MC; Tregnaghi A; Del Fiore P; Nitti D; Rossi CR
    Cancer; 2010 Mar; 116(5):1201-9. PubMed ID: 20066719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The analysis of the outcomes and factors related to iliac-obturator involvement in cutaneous melanoma patients after lymph node dissection due to positive sentinel lymph node biopsy or clinically detected inguinal metastases.
    Zdzienicki M; Rutkowski P; Nowecki ZI; van Akkooi AC; Michej W; Dziewirski W; Świtaj T; Pieńkowski A; Sałamacha M; Bylina E; Eggermont AM
    Eur J Surg Oncol; 2013 Mar; 39(3):304-10. PubMed ID: 23298828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is there increased risk of local and in-transit recurrence following sentinel lymph node biopsy?
    Cerovac S; Mashhadi SA; Williams AM; Allan RA; Stanley PR; Powell BW
    J Plast Reconstr Aesthet Surg; 2006; 59(5):487-93. PubMed ID: 16631558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of nonsentinel lymph node positivity in patients with a positive sentinel node for melanoma.
    Sabel MS; Griffith K; Sondak VK; Lowe L; Schwartz JL; Cimmino VM; Chang AE; Rees RS; Bradford CR; Johnson TM
    J Am Coll Surg; 2005 Jul; 201(1):37-47. PubMed ID: 15978442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histological features of melanoma sentinel lymph node metastases associated with status of the completion lymphadenectomy and rate of subsequent relapse.
    Govindarajan A; Ghazarian DM; McCready DR; Leong WL
    Ann Surg Oncol; 2007 Feb; 14(2):906-12. PubMed ID: 17136471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accuracy of lymphatic mapping and sentinel lymph node biopsy after previous wide local excision in patients with primary melanoma.
    Gannon CJ; Rousseau DL; Ross MI; Johnson MM; Lee JE; Mansfield PF; Cormier JN; Prieto VG; Gershenwald JE
    Cancer; 2006 Dec; 107(11):2647-52. PubMed ID: 17063497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Sentinel lymph node biopsy for melanoma: prognostic value and disadvantages in 300 patients].
    de Vries M; Jager PL; Suurmeijer AJ; Plukker JT; van Ginkel RJ; Hoekstra HJ
    Ned Tijdschr Geneeskd; 2005 Aug; 149(33):1845-51. PubMed ID: 16128183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patterns of first-recurrence and post-recurrence survival in patients with primary cutaneous melanoma after sentinel lymph node biopsy.
    Dalal KM; Patel A; Brady MS; Jaques DP; Coit DG
    Ann Surg Oncol; 2007 Jun; 14(6):1934-42. PubMed ID: 17406951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Morbidity and recurrence after completion lymph node dissection following sentinel lymph node biopsy in cutaneous malignant melanoma.
    Guggenheim MM; Hug U; Jung FJ; Rousson V; Aust MC; Calcagni M; Künzi W; Giovanoli P
    Ann Surg; 2008 Apr; 247(4):687-93. PubMed ID: 18362633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sentinel lymph node biopsy for cutaneous melanoma: the Stanford experience, 1997-2004.
    Berk DR; Johnson DL; Uzieblo A; Kiernan M; Swetter SM
    Arch Dermatol; 2005 Aug; 141(8):1016-22. PubMed ID: 16103331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors predicting the risk of in-transit recurrence after sentinel lymphonodectomy in patients with cutaneous malignant melanoma.
    Kretschmer L; Beckmann I; Thoms KM; Mitteldorf C; Bertsch HP; Neumann C
    Ann Surg Oncol; 2006 Aug; 13(8):1105-12. PubMed ID: 16865591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of nonsentinel lymph node involvement in patients with a positive sentinel lymph node in malignant melanoma.
    Page AJ; Carlson GW; Delman KA; Murray D; Hestley A; Cohen C
    Am Surg; 2007 Jul; 73(7):674-8; discussion 678-9. PubMed ID: 17674939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.